Variation in Colonoscopy Performance Measures According to Procedure Indication.


Journal

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
ISSN: 1542-7714
Titre abrégé: Clin Gastroenterol Hepatol
Pays: United States
ID NLM: 101160775

Informations de publication

Date de publication:
05 2020
Historique:
received: 02 07 2019
accepted: 02 08 2019
pubmed: 26 8 2019
medline: 19 8 2021
entrez: 26 8 2019
Statut: ppublish

Résumé

Most fulfillment and benchmarking information for colonoscopy quality indicators has been obtained from studies of primary screening colonoscopies. We analyzed differences in the fulfillment of colonoscopy quality indicators based on the indication for endoscopy. We performed an observational, multicenter, cross-sectional study of 14,867 patients who underwent endoscopy procedures for gastrointestinal symptoms (40.3%), a positive result from a fecal immunochemical test (36.0%), postpolypectomy surveillance (15.3%), or primary screening (8.4%), from February 2016 through December 2017 at 14 centers in Spain. We evaluated rates of adequate colon cleansing, cecal intubation, adenoma detection, and colorectal cancer detection, among others. We used findings from primary screening colonoscopies as the reference standard. Fewer than 90% of patients had adequate bowel preparation; 83.1% of patients with gastrointestinal symptoms had adequate bowel preparation (odds ratio [OR] compared with patients with primary screening colonoscopies, 0.62; 95% CI, 0.49-0.78) and 85.3% of patients receiving postpolypectomy surveillance had adequate bowel preparation (OR, 0.71; 95% CI, 0.55-0.91). The cecal intubation rate was also lower in patients with gastrointestinal symptoms (93.1%) (OR, 0.34; 95% CI, 0.22-0.52). The adenoma detection rate was higher in patients with a positive result from a fecal immunochemical test (46.4%) (OR, 2.01; 95% CI, 1.71-2.35) and in patients undergoing postpolypectomy surveillance (48.2%) (OR, 1.41; 95% CI, 1.20-1.67). The highest proportion of patients with colorectal cancer was in the gastrointestinal symptom group (5.1%) (OR, 5.24; 95% CI, 2.30-11.93) and the lowest was in patients undergoing surveillance (0.8%) (OR, 0.83; 95% CI, 0.32-2.14). Fulfillment of colonoscopy performance measures varies substantially by indication. Policies addressing performance measures beyond colonoscopy screening procedures should be developed. Benchmarking recommendations could be adjusted according to colonoscopy indication.

Sections du résumé

BACKGROUND & AIMS
Most fulfillment and benchmarking information for colonoscopy quality indicators has been obtained from studies of primary screening colonoscopies. We analyzed differences in the fulfillment of colonoscopy quality indicators based on the indication for endoscopy.
METHODS
We performed an observational, multicenter, cross-sectional study of 14,867 patients who underwent endoscopy procedures for gastrointestinal symptoms (40.3%), a positive result from a fecal immunochemical test (36.0%), postpolypectomy surveillance (15.3%), or primary screening (8.4%), from February 2016 through December 2017 at 14 centers in Spain. We evaluated rates of adequate colon cleansing, cecal intubation, adenoma detection, and colorectal cancer detection, among others. We used findings from primary screening colonoscopies as the reference standard.
RESULTS
Fewer than 90% of patients had adequate bowel preparation; 83.1% of patients with gastrointestinal symptoms had adequate bowel preparation (odds ratio [OR] compared with patients with primary screening colonoscopies, 0.62; 95% CI, 0.49-0.78) and 85.3% of patients receiving postpolypectomy surveillance had adequate bowel preparation (OR, 0.71; 95% CI, 0.55-0.91). The cecal intubation rate was also lower in patients with gastrointestinal symptoms (93.1%) (OR, 0.34; 95% CI, 0.22-0.52). The adenoma detection rate was higher in patients with a positive result from a fecal immunochemical test (46.4%) (OR, 2.01; 95% CI, 1.71-2.35) and in patients undergoing postpolypectomy surveillance (48.2%) (OR, 1.41; 95% CI, 1.20-1.67). The highest proportion of patients with colorectal cancer was in the gastrointestinal symptom group (5.1%) (OR, 5.24; 95% CI, 2.30-11.93) and the lowest was in patients undergoing surveillance (0.8%) (OR, 0.83; 95% CI, 0.32-2.14).
CONCLUSIONS
Fulfillment of colonoscopy performance measures varies substantially by indication. Policies addressing performance measures beyond colonoscopy screening procedures should be developed. Benchmarking recommendations could be adjusted according to colonoscopy indication.

Identifiants

pubmed: 31446179
pii: S1542-3565(19)30910-3
doi: 10.1016/j.cgh.2019.08.035
pii:
doi:

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1216-1223.e2

Investigateurs

Rodrigo Jover (R)
Carolina Mangas-Sanjuan (C)
Enrique Santana (E)
Juan A Casellas (JA)
Francisco A Ruíz-Gómez (FA)
Eva Serrano (E)
Cristina Mira (C)
Adolfo Suárez (A)
Verónica Álvarez-García (V)
Olegario Castaño (O)
Lorena Blanco (L)
Natalia González (N)
Javier Lara (J)
Enrique Quintero (E)
H Clínic (H)
María Pellisé (M)
Liseth Rivero (L)
Josep Llach (J)
Henry Cordova (H)
Isis Araujo (I)
Ariadna Sánchez (A)
Ingrid Ordas (I)
Karina Lisette (K)
H Del Mar (H)
Agustín Seoane (A)
Marco Antonio Álvarez-González (MA)
Laura Carot (L)
Inés Ana Ibáñez (IA)
Faust Riu (F)
Miguel Pantaleón (M)
Josep María Dedeu (JM)
Luis Eugenio Barranco (LE)
Akiko Ono (A)
Joaquín Cubiella (J)
Elena Rodríguez-Camacho (E)
Franco Baiocchi (F)
Coral Tejido (C)
Luis Bujanda (L)
Isabel Portillo (I)
Isabel Idígoras (I)
Isabel Bilbao (I)
Maite Herráiz (M)
Cristina Carretero (C)
Maite Betés (M)
Ángeles Pizarro (Á)
Marta Ponce (M)
Marco Bustamante (M)
Vicente Pons (V)
Lidia Argüello (L)
Carla Satorres (C)
Pilar Díez-Redondo (P)
Henar Núñez (H)
Victoria Busto (V)
Lucía Cid-Gómez (L)
Vicent Hernández (V)
Luisa de Castro (L)
Nereida Fernández-Fernández (N)
Alfonso Martínez-Turnes (A)
Beatriz Romero-Mosquera (B)
Romina Fernández-Poceiro (R)
Alberto Lué (A)
Ángel Lanas (Á)
Angel Ferrández (A)
Pilar Roncales (P)

Informations de copyright

Copyright © 2020 AGA Institute. Published by Elsevier Inc. All rights reserved.

Auteurs

Carolina Mangas-Sanjuan (C)

Department of Gastroenterology, Hospital General Universitario de Alicante, Instituto de Investigación Sanitaria and Biomédica de Alicante, ISABIAL, Alicante, Spain.

Enrique Santana (E)

Department of Gastroenterology, Hospital General Universitario de Alicante, Instituto de Investigación Sanitaria and Biomédica de Alicante, ISABIAL, Alicante, Spain.

Joaquín Cubiella (J)

Department of Gastroenterology, Complexo Hospitalario de Ourense, Instituto de Investigación Biomédica de Ourense, Pontevedra y Vigo, Ourense, Spain.

Elena Rodríguez-Camacho (E)

Dirección Xeral de Saúde Pública, Consellería de Sanidade, Santiago de Compostela, Spain.

Agustín Seoane (A)

Department of Gastroenterology, Parc de Salut Mar, Hospital del Mar, Barcelona, Spain.

Marco Antonio Alvarez-Gonzalez (MA)

Department of Gastroenterology, Parc de Salut Mar, Hospital del Mar, Barcelona, Spain.

Adolfo Suárez (A)

Department of Gastroenterology, Hospital Universitario Central de Asturias, Oviedo, Spain.

Verónica Álvarez-García (V)

Department of Gastroenterology, Hospital Universitario Central de Asturias, Oviedo, Spain.

Natalia González (N)

Department of Gastroenterology, Hospital Universitario de Canarias, Instituto Universitario de Tecnologías Biomédicas and Centro de Investigación Biomédica de Canarias, Universidad de La Laguna, Santa Cruz de Tenerife, Spain.

Alberto Luè (A)

Department of Gastroenterology, Hospital Clínico Universitario Lozano Blesa, Aragon Health Research Institute, Zaragoza, Spain.

Lucía Cid-Gomez (L)

Department of Gastroenterology, Complexo Hospitalario Universitario de Vigo, Instituto de Investigación Biomédica, Xerencia de Xestión Integrada de Vigo, Vigo, Spain.

Marta Ponce (M)

Department of Gastroenterology, Hospital Universitario La Fe, Valencia, Spain.

Luis Bujanda (L)

Department of Gastroenterology, Biodonostia Medical Research Institute, San Sebastián, Spain.

Isabel Portillo (I)

BioCruces Health Research Institute, Colorectal Screening Program, Basque Health Service, Barakaldo, Spain.

María Pellisé (M)

Department of Gastroenterology, Hospital Clínic de Barcelona, Barcelona, Spain.

Pilar Díez-Redondo (P)

Endoscopy Unit, Hospital Universitario Rio Hortega, Valladolid, Spain.

Maite Herráiz (M)

Department of Gastroenterology, Clínica Universitaria and Medical School, University of Navarra, Navarra, Spain.

Akiko Ono (A)

Unidad de Gestión Clínica de Digestivo, Hospital Universitario Virgen de la Arrixaca, Instituto Murciano de Investigación Biosanitaria, Murcia, Spain.

Ángeles Pizarro (Á)

Department of Gastroenterology, Hospital Universitario Virgen del Rocío, Sevilla, Spain.

Pedro Zapater (P)

Unit of Clinical Pharmacology, Hospital General Universitario de Alicante, Instituto de Investigación Sanitaria y Biomédica de Alicante (ISABIAL) Alicante, Spain.

Rodrigo Jover (R)

Department of Gastroenterology, Hospital General Universitario de Alicante, Instituto de Investigación Sanitaria and Biomédica de Alicante, ISABIAL, Alicante, Spain. Electronic address: rodrigojover@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH